Side effects often return briefly after each dose increase this is normal
Discuss your medical history and symptoms during the consultation
Microdosing GLP-1 medications is largely experimental and lacks scientific support from clinical trials
Chan B, Xuan S, Horton M, Zhang D
Introduction Recently, a consensus on a new nomenclature has been proposed, with metabolic dysfunction-associated steatotic liver disease (MASLD) replacing nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatohepatitis (MASH) replacing nonalcoholic steatohepatitis (NASH)
Starting GLP-1 medications prematurely can cause increased nausea and vomiting, delayed gastric emptying, compromised nutritional intake, dehydration, and potentially delayed wound healing